이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Clovis Oncology 대차 대조표 상태
재무 상태 기준 확인 0/6
Clovis Oncology has a total shareholder equity of $-417.9M and total debt of $660.4M, which brings its debt-to-equity ratio to -158%. Its total assets and total liabilities are $346.8M and $764.7M respectively.
주요 정보
-158.0%
부채 비율
US$660.38m
부채
| 이자 보상 비율 | n/a |
| 현금 | US$58.32m |
| 주식 | -US$417.89m |
| 총 부채 | US$764.66m |
| 총 자산 | US$346.78m |
최근 재무 상태 업데이트
Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10
Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05재무 상태 분석
단기부채: CLVS.Q has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
장기 부채: CLVS.Q has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
부채 대 자본 내역 및 분석
부채 수준: CLVS.Q has negative shareholder equity, which is a more serious situation than a high debt level.
부채 감소: CLVS.Q's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
대차 대조표
현금 런웨이 분석
과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.
안정적인 현금 활주로: Insufficient data to determine if CLVS.Q has enough cash runway based on its current free cash flow.
예측 현금 활주로: Insufficient data to determine if CLVS.Q has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.